Study found ivosidenib is well tolerated and resulted in a favorable OS benefit vs placebo in advanced IDH1mutated cholangiocarcinoma, revealing a compelling clinical benefit of ivosidenib in this clinical setting ja.ma/3i2yJvD #GICSM

Study found ivosidenib is well tolerated and resulted in a favorable OS benefit vs placebo in advanced IDH1mutated cholangiocarcinoma, revealing a compelling clinical benefit of ivosidenib in this clinical setting ja.ma/39wefXz #GICSM

Cohort study of 634 patients w metastatic #ProstateCancer showed distinct molecular patterns assoc'd w luminal & basal subtypes, & subtypes were prognostic, with stronger benefit from androgen inhibitor therapies in pts w luminal subtype ja.ma/2W4k4IA #PCSM

Results from the STIMULI trial by Solange Peters, Martin Reck, and colleagues are now online in Annals of Oncology. Results showed no improvement for PFS & OS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in limited disease #SCLC ➡️ bit.ly/3zL3ACR

#ESMOasiaweek21: registration is open & free of charge! A week of top events ✅ ESMO Asia Highlights of the Year Meeting ✅ Pan Asian adapted Guidelines lectures ✅Policy sessions ✅ #VirtualPlenary sessions ✅ Preceptorship courses 👉ow.ly/fCjq50Gfzuj

Access to #cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional #survey: bit.ly/3EX6Z5A #oncology #medicine #treatment #MedTwitter The Lancet Oncology

Therapeutic drug monitoring in #oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for #imatinib therapy: bit.ly/3FiN2WO IATDMCT Oncology Advance #cancer #guidelines #MedTwitter #healthcare #medicine

Cancer programs with high use of neoadjuvant chemotherapy for patients with advanced ovarian cancer achieve similar gains median survival and lager improvements in short-term mortality compared with programs with low use ja.ma/3F3NMPz #GynCSM

Grade 2 is the grey zone for treatment decisions in early #BreastCancer . Could the development of a model using deep learning allow an improved risk stratification? Check out this #openaccess article in Annals of Oncology: annalsofoncology.org/article/S0923-… #bcsm Mattias Rantalainen Biostatistics Group at MEB, Karolinska Institutet

New #JITC article: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach ow.ly/cs8t50GlzlN Tomas G. Neilan, MD, MPH

In a phase III trial in 982 men with androgen signalling inhibitor-naive mCRPC, adding apalutamide to abiraterone–prednisone improved rPFS (median 24 vs 16.6 months; HR 0.70; P<00001), but not mOS (36.2 vs 33.7 months; HR 0.95; P=0.50): thelancet.com/journals/lanon… #PCSM #uroonc

📣Today we share #Review "Overview of Immune Checkpoint Inhibitors Therapy for #Hepatocellular #Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice" Find Full-Text on👉mdpi.com/2072-6694/11/1…

The Use of #Mobile Applications for the Diagnosis and Treatment of Tumors in Orthopaedic #Oncology – a #SystematicReview: bit.ly/3lIymbR #cancer #Orthopaedics

Neoadjuvant PD1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal #cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial: bit.ly/3GlAQ8p

In a phase II study of the ATR inhibitor ceralasertib plus durvalumab in pts with advanced-stage melanoma with progression on prior anti-PD-1 therapy, the ORR was 31%, the DCR was 63.3%, mPFS was 7.1 months & mOS was 14.2 months: annalsofoncology.org/article/S0923-… #melsm #ImmunoOnc

New #JITC article: Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab ow.ly/NItm50GyIpC Allison Betof Warner, MD, PhD Jedd Wolchok Michael Postow

Does tumor burden impact tumor immunity and response to immunotherapy? Important review on this topic NatureRevClinOncol ow.ly/rFWA50GNIpz #JITC SM Moshe Ornstein MD

In a first-in-human phase I study of the anti–TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab, treatment seemed well tolerated. ORRs were 0-26%, being highest with the combination in pts with anti-PD-1/PD-L1–naïve NSCLC: annalsofoncology.org/article/S0923-…

In a randomized 1L phase 3 (eXalt3) trial in #ALK-positive #NSCLC, PFS was significantly longer with ensartinib vs crizotinib (NR vs 12.7 months, HR=0.45) by BIRC with a favorable safety profile. CNS ORR was 64% with ensartinib vs 21% with crizotinib ja.ma/3HyIUU4 #LCSM

Delighted to be the CME partner for this important launch during #ASCO22